CD274 and small cell lung carcinoma: The IMpower133 phase III trial evaluated the efficacy of adding atezolizumab, a PD-L1 inhibitor, to standard chemotherapy with carboplatin and etoposide (CP/ET) in treatment-naive patients with extensive-stage small cell lung cancer (ES-SCLC).